Premium
Use of propranolol for parotid hemangioma
Author(s) -
Chang Lei,
Jin Yunbo,
Lv Dongze,
Ying Hanru,
Wang Tianyou,
Qiu Yajing,
Ma Gang,
Chen Hui,
Yu Wenxin,
Yang Xi,
Lin Xiaoxi
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24308
Subject(s) - propranolol , hemangioma , medicine , infantile hemangioma , lesion , hemodynamics , head and neck , radiology , prospective cohort study , surgery , cardiology , anesthesia
Background Few specific reports have addressed propranolol as a treatment for parotid hemangioma, and its mechanism remains unclear. Methods Eighty‐seven patients were recruited in this prospective study. Ten patients underwent detailed color Doppler examination. The depths, vessel densities, and resistant indices of 10 lesions were recorded and analyzed before treatment and at 1 and 3 months after treatment. Results The overall responses were “bad” in 2 cases, “stable” in 4 cases, “good” in 53 cases, and “excellent” in 28 cases. Hemangioma regrowth was observed in 11 cases (12.6%). The parents of 18 patients (20.7%) complained that their children experienced minor discomfort during therapy. The lesion depths, vessel densities, and resistant indices were altered after propranolol treatment. Conclusion Propranolol can significantly reduce the sizes of parotid hemangiomas with minor side effects. Hemodynamic changes might play an important role in the course of propranolol treatment. © 2015 Wiley Periodicals, Inc. Head Neck 38 : E1730–E1736, 2016